abiraterone and Genetic Predisposition
abiraterone has been researched along with Genetic Predisposition in 2 studies
Research
Studies (2)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Antonarakis, ES; Chen, Y; Isaacs, WB; Lai, Z; Liang, C; Lu, C; Luber, B; Luo, J; Piana, D; Silberstein, JL; Wang, H | 1 |
Antonarakis, ES; Carducci, MA; Chen, Y; Denmeade, SR; Eisenberger, MA; Lu, C; Luber, B; Luo, J; Nadal, R; Nakazawa, M; Paller, CJ; Wang, H | 1 |
Other Studies
2 other study(ies) available for abiraterone and Genetic Predisposition
Article | Year |
---|---|
Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.
Topics: Aged; Androgen Antagonists; Androstenes; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Benzamides; Biomarkers, Tumor; BRCA1 Protein; BRCA2 Protein; Clinical Decision-Making; DNA Mutational Analysis; DNA Repair Enzymes; Genetic Predisposition to Disease; Germ-Line Mutation; GPI-Linked Proteins; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Proteins; Nitriles; Phenotype; Phenylthiohydantoin; Precision Medicine; Progression-Free Survival; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Time Factors; Treatment Outcome | 2018 |
Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
Topics: Academic Medical Centers; Adenocarcinoma; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Baltimore; Benzamides; Biomarkers, Tumor; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Genetic Predisposition to Disease; Humans; Kallikreins; Kaplan-Meier Estimate; Male; Middle Aged; Neoplastic Cells, Circulating; Nitriles; Patient Selection; Phenotype; Phenylthiohydantoin; Predictive Value of Tests; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Protein Isoforms; Receptors, Androgen; Risk Factors; RNA, Messenger; Taxoids; Time Factors; Treatment Outcome | 2015 |